Insmed Incorporated (INSM)

From the record

Insmed Incorporated's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Insmed Incorporated's 10 filed years say what it did: it rose in 7 of 7 years; it never fell from a peak; net income was positive in 0 of 10 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Insmed Incorporated lost about 173 cents for every dollar of shareholders' money, and gross profitability: its products earned about 21 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 67 cents per dollar of assets, and net share issuance: its share count grew 21.3% over the year (the filed statements).

From the record

Insmed Incorporated's standing among 315 graded names in its industry family: revenue of $606 million in fiscal 2025 ranks in the top 18% by size; a net margin of -210.5% ranks in the bottom 46%; revenue growth of 35.2% a year over the last 3 filed years ranks in the top 28% (its annual reports).

From the record

Insmed Incorporated's leadership, from its insiders' filings and its current reports: the chief executive on the record is Lewis, William (Chair and CEO, as filed), filing under that title since 2012-09-12, 14.2 years (top 6% of its family); the 16 officers and directors filing in the last fifteen months have been on the record a median of 7.5 years (top 23%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 16 people in charge now (top 46%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Insmed Incorporated's room to grow, from the newest filed statements (fiscal 2025): cash of $510 million against debt of $541 million leaves -1.3% of its assets as net cash, bottom 13% of its family; cash from operations less capital spending is -159.6% of revenue (bottom 45%); a gross margin of 79.7% (top 34%); research spending of 127.2% of revenue (top 48%) (its annual report).

From the record

Insmed Incorporated's growth drivers, from the filed years to fiscal 2025: the newest year grew 66.8% (top 19%); research spending grew 24.7% a year (top 19%); capital spending grew 48.8% a year (top 15%) (its annual reports). Insmed Incorporated reported 2 product lines in fiscal 2025: ARIKAYCE at $434 million (72%), BRINSUPRI at $173 million (28%); 1 of 1 grew against the year before (its annual report).

From the record

Insmed Incorporated's newest year against its own record: revenue of $606 million in fiscal 2025 came in 37% above the $443 million its prior three years' pace pointed to (top 21% of its family); net income of $1.3 billion against a prior three-year average of $715 million (bottom 19%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 45%) (its annual reports).